Preclinical Antibody-Antigen Fusion Platform for Cancer Vaccines

Q: How do you ensure the fusion protein remains an 'agonist' rather than a 'blocker'?

We utilize bivalent architectures like scFv-Fc-scFv designed to mirror natural ligand signaling. Agonistic activity is verified via luciferase reporter assays tracking pathway activation like NF-κB.

Q: What is the typical size of antigens that can be successfully fused?

We handle antigens from small neoantigen peptides (10-30 aa) to large protein subunits (>50 kDa), using optimized linker designs and expression platforms like BEVS or Mammalian cells.

Q: Do you offer help with cross-species reactivity studies?

Yes, we provide species-specific binding assays and can engineer surrogate murine fusion constructs for preclinical efficacy validation to ensure translatability.

Q: What is the primary readout for 'Half-life extension' in your platform?

We monitor serum concentration kinetics via PK sampling in animal models, calculating the elimination half-life and correlating it with persistent T-cell responses and tumor growth inhibition.

Engineering "Precision Guided Missiles" for targeted immune activation. Creative Biolabs provides a specialized preclinical developmentplatform for antibody-antigen fusion proteins, designed to deliver tumor antigens directly to the core of the immune response.

Our platform integrates bivalent scFv-Fc technology to mimic natural ligands, efficiently cross-linking and activating critical immune checkpoints like OX40. By fusing targeted antibody fragments with personalized tumor antigens, we create "ready-to-use" immunopotentiators that enhance T-cell activity while ensuring superior protein stability and extended half-life.

Request Preclinical Project Design

Targeted Agonism: Bridging Antibody Engineering with Vaccine Potency

Traditional vaccines rely on passive uptake, often resulting in sub-optimal priming. Our antibody-antigen fusion platform represents a strategic leap forward, as highlighted in recent 2023 npj Vaccines research (Mahasongkram et al.):

▶ Active Receptor Cross-linking: Utilizing bivalent human scFvs to engage receptors like OX40 or CD40, triggering potent downstream signaling that mirrors natural membrane-bound ligands.
▶ Selective T-Cell Potentiation: Directing antigens to effector T cells and APCs simultaneously, ensuring that the immune system's "activation signal" is coupled with the "target blueprint."
▶ Optimized Pharmacokinetics: Fc-fusion architectures significantly extend the therapeutic window, allowing for reduced dosing frequency while maintaining high protective titers in preclinical animal models.

Specialized Preclinical Fusion Solutions

We offer end-to-end expertise to synthesize and validate high-affinity antibody-antigen conjugates:

Modular scFv-Antigen Design

strategic assembly of single-chain variable fragments (scFv) with tumor antigens. We optimize linker flexibility and orientation to preserve epitope accessibility and binding kinetics.

Agonistic Bivalent Scaffolds

Constructing scFv-Fc-scFv bivalent molecules that target T-cell co-stimulatory ectodomains, providing the necessary mechanical tension for receptor activation.

Functional Signaling Verification

Quantitative in vitro assessment of NF-κB or MAPK pathway activation following fusion protein binding, verifying the agonistic nature of the construct.

In Vivo Protective Efficacy

Monitoring T-cell infiltration and tumor volume inhibition in syngeneic models, correlating half-life extensions with overall therapeutic potency.

Featured Preclinical Focus Areas

Advancing the boundaries of targeted immunotherapy through antibody engineering:

OX40 Agonist-Antigen Fusions

Utilizing scFv-Fc scaffolds to cross-link OX40 receptors on activated T cells, significantly boosting vaccine-induced effector memory formation.

Explore OX40 Logic →

Neoantigen Delivery Missiles

Fusing personalized neoantigen peptides to targeting scFvs (e.g., anti-DEC-205) to ensure precision loading of host dendritic cells.

View Precision Suites →

Bispecific Fusion Prototypes

Engineering constructs that target two immune receptors or a tumor marker and a co-stimulatory molecule simultaneously to break TME resistance.

Learn About TME Reversal →

"Off-the-Shelf" Immune Boosters

Developing stabilized scFv-Fc-antigen prototypes that function as ready-to-use adjuvants for combination with checkpoint inhibitors.

Get Prototype Details →

Agile Preclinical Fusion Development Workflow

Our systematic pipeline ensures the transition from antibody screening to a validated lead candidate:

Step 1: Antibody Selection & scFv Design

Activities: Identification of high-affinity scFvs targeting immune receptors (e.g., OX40, CD40). We utilize phage display or hybridoma technologies to select clones with agonistic potential and optimal stability profiles.

Outcome: Validated scFv sequences ready for molecular fusion.

Step 2: Fusion Construct Assembly & Linker Tuning

Activities: Strategic fusion of antigens to the N- or C-terminus of the antibody fragment. We perform bioinformatic modeling to optimize (Gly4Ser)n linker length, ensuring that the bivalent Fc region does not sterically hinder antigen binding.

Outcome: Verified fusion blueprint with high predicted solubility.

Step 3: High-Yield Production & Characterization

Activities: Expression in mammalian (CHO/HEK293) or BEVS platforms. We perform multi-parameter quality control including SEC-MALS for purity, SPR for binding affinity, and glycosylation profiling for Fc functionality.

Outcome: Purified, standardized fusion protein lead stocks.

Step 4: Receptor Cross-linking & In Vitro Validation

Activities: Assessment of receptor clustering and downstream signaling activation in reporter cell lines. We evaluate the enhancement of primary T-cell proliferation and IFN-γ secretion following stimulation with the fusion protein.

Outcome: Functional mechanistic proof of targeted immune agonism.

Step 5: Preclinical Efficacy & Half-life Tracking

Activities: Longitudinal animal studies in syngeneic models. We track the PK/PD profile of the fusion vaccine and quantify tumor-infiltrating lymphocyte (TIL) expansion via flow cytometry to support IND-enabling data packages.

Outcome: Comprehensive preclinical report on antitumor protective efficacy.

Discuss Your Project Timeline

Proprietary Fusion Engineering Platforms

Our solutions are powered by industry-leading systems tailored for targeted immunotherapy:

Fusion-Logic AI Modeler: A sophisticated computational platform for predicting the folding stability and epitope exposure of complex antibody-antigen fusions. It minimizes the risk of aggregation and ensures maximal binding affinity.

AI-driven linker flexibility optimization
Structural simulation of bivalent receptor-Fc interactions
Stability prediction across diverse pH environments

Agonist-Sync Assay Hub: A specialized analytical suite designed to verify the agonistic activity of fusion proteins. It tracks real-time receptor clustering and subsequent intracellular signaling (e.g., TRAF recruitment).

High-sensitivity NF-κB/AP-1 luciferase reporter assays
Multiplex cytokine profiling
Species-specific binding kinetics for preclinical modeling

Half-life Immuno-Glide Suite: An engineering platform dedicated to the Fc-region modulation. We optimize the FcRn binding affinity to maximize the circulatory half-life of vaccine candidates while maintaining pro-inflammatory FcγR activity.

Customizable Fc isotypes (IgG1, IgG4) and mutations
Quantitative PK/PD modeling in murine and primate models
Stabilization of scFv fragments for long-term bioactivity

Fusion-Logic AI

Agonist-Sync Hub

Immuno-Glide Suite

Scientific Insight: scFv-Fc Fusions Targeting OX40

Enhancing T-Cell Activity via Agonistic Bivalent scFvs (Mahasongkram et al., 2023)

Innovation: Research published in Vaccines demonstrates a major breakthrough in targeted immunotherapy. By fusing two human scFvs targeting OX40 with an IgG1 Fc region, researchers created a potent bivalent fusion antibody that mimics natural ligands.

Research Highlights:

Mechanism: The scFv-Fc construct efficiently cross-links OX40 ectodomains on T cells, triggering robust activation signaling and enhancing antitumor function.
Industrial Application: This "ready-to-use" immunomodulator significantly improves protein stability and serum half-life, serving as an ideal scaffold for cancer vaccines.
Therapeutic Potential: Validates the fusion technology for developing novel vaccine adjuvants or combination therapies with checkpoint inhibitors.

OX40 fusion antibodies promote T cell survival and inhibit apoptosis.

Fig.1 OX40 fusion antibodies enhance T cell survival and reduce T cell death.^1,2

Frequently Asked Questions

Q: Why use an scFv fragment instead of a full-length antibody for the fusion?

A: scFv fragments offer superior modularity and tissue penetration due to their smaller size. When fused to an Fc region, they achieve the desired bivalency and half-life extension while providing a more flexible scaffold for attaching complex antigens without the steric hindrance often found in full IgG fusions.

Q: How do you ensure the fusion protein remains an 'agonist' rather than a 'blocker'?

A: Agonism requires receptor cross-linking and subsequent clustering. Our platform uses agonistic clones and bivalent architectures (like scFv-Fc-scFv) specifically designed to mirror ligand signaling. We verify this via our Agonist-Sync platform through luciferase reporter assays and TRAF recruitment analysis.

Q: What is the typical size of antigens that can be successfully fused?

A: We have successfully fused antigens ranging from small neoantigen peptides (10-30 amino acids) to large globular protein subunits (>50 kDa). The key is optimized linker design and expression platform selection (e.g., BEVS or Mammalian) to ensure proper folding.

Q: Do you offer help with cross-species reactivity studies?

A: Yes. For preclinical studies, it is vital to know if your human scFv cross-reacts with murine or primate targets. We provide species-specific binding assays and can engineer "surrogate" murine fusion constructs for early-stage efficacy validation.

Q: What is the primary readout for 'Half-life extension' in your platform?

A: We utilize serial PK sampling in murine or NHP models, measuring protein concentration via ELISA or radiolabeling. We calculate the elimination half-life and correlate it with the persistence of antigen-specific T-cell responses and tumor growth inhibition.

Related Resources

References:
1. Mahasongkram, Kodchakorn, et al. "Agonistic Bivalent Human scFvs-Fcγ Fusion Antibodies to OX40 Ectodomain Enhance T Cell Activities against Cancer." Vaccines 11.12 (2023): 1826.
2. Distributed under Open Access License CC BY 4.0, without modification.